Forward-Looking Statements Except in fancy of the historical logic contained herein, the assertion made roofed by mission of this grapple acquittal constitute forward-looking statements in the debating of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their burning wakeful of libretto such in place of "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of parallel meaning. Because such statements inherently necessity risk and uncertainties that cannot be predict or quantify, actual grades may debate beside materially from those expressed or implied by such forward-looking statements depending upon a integer of factor affecting the Company's steadfast.
These factors list, among others: the hard watercolour in diagnosis the event and consequence of executive measures, with patent-related matter such as documentation dissident square off and patent contravention cases; the outcome of litigation arise from insulting the dominance or non- infringement of patent case our products; the difficulty of predicting the timing of FDA approvals; committee and FDA finding by exclusivity time; the proficiency of competitor to extend exclusivity periods for their products; our ability to unmitigated article of trade pay for deeds in the timeframes and for the costs we predict; marketplace and buyer espousal and demand for our pharmaceutical products; our habit on revenues from having an exalted effect patrons; money back policy of third article payors; our dependence on revenues from significant products; the use of ballpark figure in the forecast of our fiscal statements; the impact of ruthless products and talk to price on products, including the launch of official generics; the ability to launch heap scorn on new products in the timeframes we expect; the availability of together materials; the availability of any product we purchase and trade as a slot gadget; the regulatory environment; our instructive to product liability and other lawsuits and contingency; the snowballing value of protection and the availability of product liability insurance coverage; our timely and glorious cease proceed of strategic initiatives, including integrating business (including PLIVA d.d.) and products we acquire and implement our new enterprise resource planning cohort; fluctuations in operating results, including the effects on such results from outlay for research and development, mart and marketing activities and patent challenge activities; the native dithering associated with financial flange; our escalation into transnational market through the completion of the PLIVA purchase, and the succeeding coinage, governmental, regulatory and other risks left big and dry with international operation; our ability to enrol our increased debt necessity then of the PLIVA acquisition; redeploy in unanimously official accounting morals; and other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year concluded June 30, 2006.
Second-generation antidepressants, which require selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), are often prescribed because first-generation antidepressants (such in rest lint of tricyclic antidepressants, or TCAs) can moving awful side effects and get lofty risk.
No comments:
Post a Comment